Skip to main content

. 1993 May 8;306(6887):1239–1240. doi: 10.1136/bmj.306.6887.1239

Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance?

H A Davies ¹, L Lennard ¹, J S Lilleyman ¹

PMCID: PMC1677595 PMID: 8499854

1239

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Bruckner H. W., Motwani B. T. Applications of LhRh agonists against a wide range of gynecologic cancers. J Clin Oncol. 1989 Jun;7(6):816–817. doi: 10.1200/JCO.1989.7.6.816. [DOI] [PubMed] [Google Scholar]
Lennard L., Lilleyman J. S., Van Loon J., Weinshilboum R. M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990 Jul 28;336(8709):225–229. doi: 10.1016/0140-6736(90)91745-v. [DOI] [PubMed] [Google Scholar]
Lennard L., Singleton H. J. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr. 1992 Nov 27;583(1):83–90. doi: 10.1016/0378-4347(92)80347-s. [DOI] [PubMed] [Google Scholar]
Smith S. D., Rosen D., Trueworthy R. C., Lowman J. T. A reliable method for evaluating drug compliance in children with cancer. Cancer. 1979 Jan;43(1):169–173. doi: 10.1002/1097-0142(197901)43:1<169::aid-cncr2820430125>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
Tebbi C. K., Cummings K. M., Zevon M. A., Smith L., Richards M., Mallon J. Compliance of pediatric and adolescent cancer patients. Cancer. 1986 Sep 1;58(5):1179–1184. doi: 10.1002/1097-0142(19860901)58:5<1179::aid-cncr2820580534>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES